Skip to main content

Table 6 In vivo individual risk of bias

From: Comprehensive preclinical studies on the bioactivity of Orbignya phalerata Mart. (Babassu) and its derived products: a systematic review

  1. Domains: D1—sequence generation; D2—baseline characteristics; D3—allocation concealment; D4—random housing; D5—blinding (performance bias); D6—random outcome assessment; D7—blinding (detection bias); D8—incomplete outcome data; D9—selective outcome reporting; D10—other sources of bias. Total: 130 (100%); (+) Yes: 45 (34.61%); (−) No: 5 (3.85%); (?) Unclear: 80 (61.54%) [19]